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Abstract
Background: The antiretroviral therapy (ART) adherence club (AC) differentiated service delivery model, where
clinically stable ART patients receive their ART refills and psychosocial support in groups has supported clinically
stable patients’ retention and viral suppression. Patients and health systems could benefit further by reducing visit
frequency and increasing ART refills. We designed a cluster-randomized control trial comparing standard of care
(SoC) ACs and six-month ART refill (Intervention) ACs in a large primary care facility in Khayelitsha, South Africa.
Methods: Existing ACs were randomized to either the control (SOC ACs) or intervention (Intervention ACs) arm.
SoC ACs meet five times annually, receiving two-month ART refills with a four-month ART refill over year-end. Blood
is drawn at the AC visit ahead of the clinical assessment visit. Intervention ACs meet twice annually receiving six-
month ART refills, with a third individual visit for routine blood collection anytime two-four weeks before the
annual clinical assessment AC visit. Primary outcomes will be retention in care, annual viral load assessment
completion and viral load suppression. (<400copies/mL) after 2 years.
Ethics approval has been granted by the University of Cape Town (HREC 652/2016) and the Medecins Sans
Frontieres (MSF) Ethics Review Board (#1639). Results will be published in peer-reviewed journals and made widely
available through presentations and briefing documents.
Discussion: Evaluation of an extended ART refill interval in adherence clubs will provide evidence towards novel
model adaptions that can be made to further improve convenience for patients and leverage health system
efficiencies.
Trial registration: Registered with the Pan African Clinical Trial Registry: PACTR201810631281009. Registered 11
September 2018.
Keywords: Extended dispensing intervals, Antiretrovirals, Differentiated service delivery, HIV
Background
South Africa is home to the largest number of people
living with HIV (PLHIV), an estimated 7.9 million
people. In 2017, it was estimated that 55.7% of PLHIV in
South Africa were on antiretroviral therapy (ART) [1].
In February 2018, the South African president commit-
ted to starting another 2 million PLHIV by 2020 towards
ensuring South Africa meets its target of 81% by the end
of 2020 [2, 3]. To achieve these targets, the already over-
burdened health system needs to find ways to attract
and retain significantly more patients on ART.
Differentiated models of ART delivery for patients that
are otherwise healthy and clinically stable on ART, at-
tempt to make ongoing access to ART refills and clinical
management more convenient and easily accessible in
order to support continued adherence to treatment on a
long-term basis. Such models have been shown to be
feasible to implement, acceptable to patients with good
retention and viral suppression outcomes. These models
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can also be leveraged to improve health system efficiency
in an era with limited resources to achieve ambitious
targets [4–8]. One such differentiated ART delivery
model is the ART adherence club (AC), originally a dem-
onstration project by Médecins Sans Frontières (MSF) in
Khayelitsha, South Africa. The AC model was created to
and has supported long-term adherence and retention of
clinically stable ART patients [4, 9–14]. It has been en-
dorsed in a number of sub-Saharan African country pol-
icies [15–17], including South Africa, where it has been
implemented at scale [18].
Novel adaptations to differentiated ART delivery
models such as ACs are needed in order to further in-
crease convenience and access for patients and expand
ART access within a context of declining resources [19].
One possible adaptation is to reduce the frequency of
visits by increasing the amount of ART dispensed at
each refill. This would allow for an increase in the num-
ber of ACs managed by the same staff complement, and
could further decongest facilities, making space for new
patients to start ART and for patients receiving an ART
regimen that is failing and those presenting to care with
advanced HIV disease to be more intensively clinically
managed.
In the World Health Organisation’s (WHO) updated
2016 consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection, WHO
recommends that clinically stable patients can receive
ART refills every 3–6 months [20]. However, there is a
paucity of retention and viral suppression evidence sup-
porting longer intervals (e.g. 4–6 months). Evidence be-
yond 3-month ART refills is needed before health
authorities invest in changing their supply chain man-
agement system to support such longer ART refills
periods (see concerns raised in pre-study engagment,
Additional file 1). This study aims to provide high-qual-
ity evidence on the effect of extended ART dispensing
intervals on sustained retention in care and viral
suppression.
Methods
Study aims & objectives
The overall aim of this project is to investigate the im-
pact of extended ART dispensing intervals and less fre-
quent psychosocial support on retention in care and
viral suppression among clinically stable ART patients in
ACs.
1. Primary objective
To compare the retention, viral load assessment
completion and viral suppression outcomes of
patients receiving their ART refill through standard
of care (SOC) ACs and six-month ART refill
(Intervention) ACs over 24 months.
2. Secondary objectives
To determine:
a. Medicine supply chain feasibility of Intervention
ACs implementation, including medicine losses and
wastage associated with the six-month supply of
ART.
b. Impact of Intervention ACs model on clinic
congestion.
Study design
This is a cluster-randomized control trial to evaluate
whether patients in Intervention ACs have non-inferior
retention and viral load assessment and viral suppression
outcomes compared to those in SOC ACs.
Setting
The study will take place in Khayelitsha, a peri-urban
area home to approximately 500 000 people. The com-
munity is of low socioeconomic status with high levels
of HIV (antenatal HIV prevalence of 34% in 2016) and
high levels of unemployment [21]. The participants will
be recruited from Ubuntu Site B clinic’s existing ACs. A
summary of the study site is provided in Table 1.
Study population
Participants will be stable HIV-positive adults on ART
who are currently in an AC at the study site. ACs will be
recruited at their routine AC visit, which occurs five
times per year. Study inclusion criteria exist at both AC
and individual level.
AC inclusion criteria
 > 90% of patients in the AC consent to be enrolled
in study prior to randomization
AC exclusion criteria
 ACs catering to patients who require more regular
clinical follow-up than a yearly visit (e.g. family ACs,
youth ACs)
 ACs facilitated by nurses with limited group
interaction/ support and/or which function more as
ART pick-up point (e.g. evening ACs)
Participant inclusion criteria
 Age 18 years or older
 On ART for at least 6 months
 Most recent documented viral load < 400 copies/mL
(not older than 12 months)
 Able to provide informed consent for research
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Participant exclusion criteria
 Intention to relocate out of Cape Town permanently
during the study period
Description of intervention and control
A description of SOC ACs and Intervention ACs is pro-
vided below and summarized in Table 1.
The SOC ACs
Participants in the SoC ACs will continue to be provided
with their ART refill, clinical care and support following
the current Western Cape provincial AC guidelines. At
time of protocol submission, SOC ACs were groups of
25–30 stable patients who had been on ART for 6
months or more, had an undetectable viral load, and
were referred by a clinician to the model of care. SOC
ACs are facilitated by a lay healthcare worker and meet
five times per year (bi-monthly with a four-month gap
over the end of the year to support migration patterns)
for a group support session, a brief symptom check and
distribution of pre-packed ART with referral by the lay
provider to a nurse based at the clinic if necessary. At
one of these visits the patient’s blood is taken by a nurse
for routine blood monitoring, including viral load. At
the following AC visit, each AC member has their an-
nual clinical assessment with a nurse.
Patients are allowed to send a treatment “buddy” to
collect their ART refill to every alternate AC. A treat-
ment buddy is a friend or family member of an AC
member requested by the AC member to collect their
ART refill at from the AC on the AC member’s behalf.
The intervention ACs
The Intervention ACs meet twice annually receiving six-
month ART refills, with the patient being asked to indi-
vidually attend a third visit for routine blood collection
anytime two-four weeks before their annual clinical as-
sessment AC visit. Patients in Intervention ACs are not
able to send a treatment “buddy” to collect their ART
refill to ensure the health system interacts with patient
at least twice a year.
In both SOC and Intervention ACs, a five-day grace
period is permitted for late attendance. In other words,
AC patients need to come within 1 week of their AC
visit to collect their ART refill or they are up-referred to
the clinician-led ART care based at the clinic. A patient
is also up-referred if they experience viral rebound (a
viral load of > 400 copies/mL) or develop another
clinical condition that requires more regular clinical sup-
port (Table 2).
Recruitment - study participation and withdrawal
processes
ACs eligible for the study will be offered study participa-
tion at a routine AC visit. After the study is explained,
the group will be afforded an opportunity to discuss and
ask questions. Thereafter each AC member present will
be asked to cast their individual vote for study participa-
tion on a named voting slip, which will folded and
placed in a closed box handled by the study staff. The
study staff will exit the venue to count the votes and will
return to inform the group of the final outcome (i.e. >
90% voted to participate or ≤ 90% voted to participate)
with each individual’s vote remaining confidential and
only known to study staff who will not disclose it to any
other person.
If more than 90% of the AC members vote in favour of
participating in the study, the AC will be enrolled in the
study. Consent procedures will take place at the same
AC visit, or over the subsequent one or two visits, if pa-
tients need more time to consider or were not present at
the study enrolment AC visit.
In the case where an individual patient does not vote
in favour of study participation, the patient will have the
choice to stay in the AC and participate in the study or
to transfer to a newly formed AC that is not participat-
ing in the study.
AC randomization will take place after all AC patients
have provided consent, or arranged to transfer out.
Randomization will be performed with the Randomize
package in Stata, ensuring balance between community
and facility ACs in each arm [22]. At the start of the fol-
lowing AC meeting, the study staff will draw an envelope
containing the randomization outcome and inform the
AC members whether their AC has been allocated to the
SOC or intervention arm (see randomization SOP in
Additional file 3). The ACs will vote on their continu-
ation in the study for a second time, following the same
procedure as the first vote.
At the AC visit after being informed of their AC study
arm, groups will be given their first study ART refill.
See Fig. 1 for more details.
Sample size and power considerations
As this study is interested in non-inferiority, all statis-
tical tests were one-tailed with an alpha of 0.025 to ad-
dress type 1 error. At time of protocol development,
Table 1 Summary of study site
Site Total on ART at site end March 2017 Date ACs started at site Total adults in ART ACs end March 2017
Ubuntu ART clinic, Khayelitsha 10252 2007 4535
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Table 2 Comparison of SOC ACs and Intervention ACs
Standard of Care ACs Intervention six-month ACs
Frequency of AC visits 2-monthly (5 per year) 6-monthly (2 per year)







Timing of routine bloods As part of AC visit As an additional individual visit,
2–4 weeks before clinical assessment
AC visit
Units of care Groups of 25–30 Groups of 25–30
Peer-based support Strong emphasis Strong emphasis




ART care based at the clinic
Up-referral to clinician-led ART care
based at the clinic
ART packing and
dispensing
Pre-packed by central dispensing
unit, supplied to clinic pharmacy and
dispensed at AC visit
Pre-packed at clinic pharmacy with
support from study team staff and
dispensed at AC visit




of contacts per year




3 (could send a “treatment buddy”
to collect ART twice)
3 (within the AC and 1 for routine bloods)
Fig. 1 Study Schema
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there were 97 eligible ACs. We assumed 10% of the ACs
were would not participate in the study leaving 87 ACs
eligible for randomization (approximately 43 per arm),
with a total of 1986 participants (993 per arm). We pro-
posed a clustered sampling strategy for our study. There
is a paucity of information in the literature regarding
correlation between individuals within ACs, therefore we
reviewed the literature relating to the clustering effect of
facilities. Thus, to account for the correlation within
clusters we assumed a correlation ranging from 0.05–
0.10 and an average cluster size of 24 [23, 24] resulting
in our estimated design effect (deff ) ranging from 2.15–
3.3. We applied the deff to our total sample size to de-
termine the effective sample size. Assuming retention in
care would range from 75 to 85% with a 10% difference
in retention in care between the control and interven-
tion groups, we estimated the power of our study to
range from 0.80–0.98. See supplementary materials for
detailed sample size calculations.
Primary outcome measures
Primary outcomes are retention in Ubuntu clinic care
(AC or clinic care), retention in AC care, annual viral
load completion rates, and VL suppression (VL < 400
copies/ml).
Secondary outcome measures
Medicine supply chain feasibility measures
1. Patient related:
a. number of study participants whose regimen
was switched during the study (including date
of switch);
b. number of study participants reporting ART
medicine losses and the reported reason for
such losses including, but not limited to, theft,
damage or destruction in the home or
unauthorized loan or provision to another
person who ran out of ART;
c. number of study participants requests for
additional ART refill supply from the clinic
pharmacy in between AC visits and the reasons
for such requests.
2. System related:
a. number of short supplies due to medicine
supply shortages, supply chain gaps and expiry
date related losses;
b. medicines quantities wasted due to any of:
expiry, re-issue, regimen switch, non-collection
or any other reason.
Clinic patient congestion impact measures
Number of clinic visits per annum (AC and non-AC
visits) for intervention arm and SOC Arm.
Data collection
Following recruitment, ACs that are eligible, consent,
and are randomized to the intervention arm will be tran-
sitioned to Intervention ACs. Duration of follow-up for
patients is identical for patients in both arms of the
studies.
Primary outcome data will be extracted from routine
clinical records including AC registers, the National
Health Laboratory Services, and patient paper and elec-
tronic records. Data will be collected for 27 months: 24
from the start of the study, with three additional months
of follow-up before closing the dataset to ascertain final
outcomes. This will be supplemented by data from the
Western Cape provincial health data center, which uses
probabilistic matching algorithms to link patient data
from different Western Cape facilities, laboratory sys-
tems and pharmacy data.
Secondary outcome data related to medicine supply
chain feasibility will be collected by the study team in
collaboration with the pharmacy staff at the study site
onto a lost drug reporting form, and will be compiled in
a study database.
Additional data on ART dispensing between study
visits and secondary outcome data related to patient visit
data will be extracted from the provincial health data
system.
Collection of participant names and other identifiers
will be restricted to informed consent documents, and a
study identification key, all of which will be kept in a
locked cabinet in the study office at MSF separate from
other study documentation and accessible only by the
MSF project coordinator and PI. These records will be
destroyed 3 years after completion of the final study re-
port by a company that destroys confidential patient
documents. All electronic records will be kept in pass-
word-protected files. All electronic communications of




Analysis will be completed using STATA 14 [22] and will
include: descriptive summary statistics of baseline pa-
tient characteristics, Kaplan-Meier estimates of time to
loss to follow-up and first unsuppressed viral load, and
calculation of the risk and hazards ratios at 12 and 24
months.
“Retention in care” will be defined as the proportion of
patients retained in ART care at Ubuntu Clinic, in or
out of an AC. If a patient transferred out of Ubuntu
clinic before 24months, he/she will be excluded from
the denominator. “Retention in club care” will be defined
as remaining a member of the original study AC at 24
months. If a patient leaves transferred out of their AC
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before 24months, he/she is excluded from the
denominator.
“Lost to follow up” is defined as patients failing to re-
turn to clinic or AC care for 3 months after a missed
visit. “Viral load completion” is defined as having a viral
load drawn within the first and second 12month period
after study start. If a patient is lost to follow-up, trans-
ferred out of clinic, or dies they are excluded from the
denominator. “Viral load suppression” is defined as <
400 copies/mL. Only those patients with a completed
viral load and retained in care at 24 months, are in-
cluded in the denominator for viral load suppression.
Patients who die or who are transferred out will be cen-
sored at the date of this outcome.
Interim analyses
12-month primary outcomes will be assessed. An inde-
pendent Data Monitoring Committee will conduct an in-
terim review of the study patient primary outcomes.
Should there be evidence of inferiority, it will be in a
position to recommend stopping the study early (and
disseminating study findings rapidly).
Secondary outcomes
Impact on intervention on clinic congestion will be eval-
uated by determining the total number of clinic visits
per annum (AC and non-AC visits) by intervention arm
participants compared with SOC arm participants. This




There are both direct and indirect economic benefits to
patients for participating in the study. If allocated to the
intervention arm, by extending the interval between AC
meetings, the financial burdens of transport, childcare
costs and possible lost employment on patients is re-
duced. The study’s results could have further indirect
benefit by stimulating policy changes, which would ex-
tend these benefits to all study participants in the long
term and possibly other ART patients in the province
and country.
Risks
Undue group influence risk
Carrying out an intervention study in a group focused
model of care requires a careful balancing of both the
group and individual rights to participate or not partici-
pate in the study. By recognising that the group itself
has a right to benefit from study participation and not to
dissolve as result of study participation or non-participa-
tion, introduces a risk of undue influence over the indi-
vidual to consent or refuse study participation. As
outlined above in the methods section, the study design
and procedures will limit this risk as follows:
 High thresholds (> 90%) have been set requiring an
overwhelming majority of the group to be in favour
of study participation for the AC to be included in
the study.
 An additional step with similar thresholds was put
in place for AC members to have a further
opportunity to consider the AC’s study participation
after being informed of the outcome of
randomization.
 When the study is introduced to the group, the
study staff will explain that all AC members have
the right to refuse participation and doing so will in
no way compromise their access to HIV
management services.
 Voting will be confidential.
Adherence risk
While the evidence set out above demonstrates that
there is limited risk that adherence will significantly de-
cline due to less frequent engagement with the health
system and with HIV positive peers on ART, this re-
mains a risk. The risk will be minimized by adherence
counseling at the AC meetings that focuses on
remaining adherent during the long gap between meet-
ings. Additionally, patients will be sent an SMS reminder
of their AC appointment date 2 weeks before the ap-
pointment date. Patients who do not attend within the
AC grace period in both arms will be contacted to re-
mind them of their missed appointment.. Viral loads will
be monitored annually and patients who are non-adher-
ent and have a non-suppressed viral load will be up-re-
ferred back to clinician-led ART care at the main clinic
for enhanced adherence and clinical support. Patients
will also be encouraged and supported to make contact
or meet up with other AC members outside of routinely
scheduled AC meetings if this may be regarded to
strengthen or maintain their support system.
Medicine loss risk
MSF has been running ACs at community venues from
2010 and from patient homes from 2012 without any re-
ported incidents of theft. In addition, AC members have
collected their ART refills from such community venues
or other AC member’s homes and returned to their own
homes without any reported incidents of theft. AC mem-
bers have stored up to 4 months of ART received at year
end in their informal housing (including shacks) in infor-
mal settlements since this provision of four-month ART
refills over year end in 2012 with no increased reporting
of medicine losses due to vulnerable living circumstances.
For these reasons, there appears to be no increased risk of
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losses of medicine due to theft or damage or destruction
within informal housing settlements.
Study staff will also assure study participants that there
will be no negative outcome should any theft, damage, de-
struction or other loss take place and inform the participat-
ing AC members that should this occur they should
immediately report such losses to their AC facilitator and/or
any staff member at the Ubuntu clinic and/or any study staff
and their lost ART medicines will immediately be replaced.
Medicine stability risk
Both the Western Cape Department of Health and
MSF procure South African registered antiretroviral
medicines (ARVs) that meet the requirements for
long-term and accelerated testing as set out in the
South African stability guidelines1 which requires that
they are proven stable at 25 °C/60 RH for the entire
shelf life and for 6 months at 40 °C /75 °C without
loss in efficacy. Khayelitsha’s average maximum tem-
peratures do not exceed 29 °C in February, which
allows scope for peak temperatures and increased
temperatures inside informal settlement environments.
The risk will be minimized by educating all study
participants to store their ART supply away from dir-
ect sunlight or source of heat and dry place within
their home.
Trial Status & Dissemination
Timelines
This manuscript is an abridged version of Version 1 of
the protocol, which was finalized in December 2016. We
are currently still following patients up, and the final 24-
month analysis will begin once data collection in
complete in early 2020. Key dates are outlined below
and in the SPIRIT figure in Table 1 (see full SPIRIT
checklist in Additional file 4, Table 3).
 Submission to Ethics Committee and Ethics
Approval: Aug-Nov 2016
 Presentation of study and AC study enrolment at
AC meetings: Feb-June 2017
 Randomization outcomes and AC withdrawal
process at AC meetings: Jul/Aug 2017
 First 6-month supply: Oct/Nov 2017
 Second 6-month supply: Mar/April 2018
 Interim data analysis March 2019
 Data Monitoring Committee review March 2019
1South African stability guidelines issued by the Medicines Control
Council version 7.1
Table 3 SPIRIT Figure of study procedure timelines
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 Data collection: Oct 2017-Sept 2019
 Data analysis: Oct - Dec 2019
 Submission for publication: March 2020
Dissemination
The results of this study will be submitted to a peer-
reviewed journal for publication and to local and inter-
national conferences. Results will also be disseminated
to Western Cape Department of Health, the City of
Cape Town, and other national ministry of health staff,
patient advocacy groups, and at appropriate HIV/AIDS
related conferences or forums.
Additional files
Additional file 1: Pre-study engagement processes. Description of the
various engagements and consultations that took place before study
protocol was submitted (DOCX 15 kb)
Additional file 2: Patient Informed Consent form. Consent form used
for study (DOCX 37 kb)
Additional file 3: Randomization SOP. The Standard operating
Procedure for how randomization was performed during study.
(DOC 132 kb)
Additional file 4: SPIRIT Checklist. (DOC 119 kb)
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